How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?

Int J Mol Sci. 2023 Jul 24;24(14):11855. doi: 10.3390/ijms241411855.

Abstract

Over the years, cancer has been affecting the lives of many people globally and it has become one of the most studied diseases. Despite the efforts to understand the cell mechanisms behind this complex disease, not every patient seems to respond to targeted therapies or immunotherapies. Drug resistance in cancer is one of the limiting factors contributing to unsuccessful therapies; therefore, understanding how cancer cells acquire this resistance is essential to help cure individuals affected by cancer. Recently, the altered microbiome was observed to be an important hallmark of cancer and therefore it represents a promising topic of cancer research. Our review aims to provide a global perspective of some cancer hallmarks, for instance how genetic and epigenetic modifications may be caused by an altered human microbiome. We also provide information on how an altered human microbiome can lead to cancer development as well as how the microbiome can influence drug resistance and ultimately targeted therapies. This may be useful to develop alternatives for cancer treatment, i.e., future personalized medicine that can help in cases where traditional cancer treatment is unsuccessful.

Keywords: altered microbiome; cancer hallmarks; carcinogenesis; drug resistance; epigenetic modifications; genetic instability; gut microbiome; human microbiome; personalized medicine.

Publication types

  • Review

MeSH terms

  • Carcinogenesis
  • Drug Resistance
  • Gastrointestinal Microbiome*
  • Humans
  • Microbiota* / genetics
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics

Grants and funding

This research was financed by Fundo Europeu de Desenvolvimento Regional (FEDER) funds through the COMPETE 2020 Operational Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through Fundação para a Ciência e a Tecnologia (FCT) in the framework of projects IF/00092/2014/CP1255/CT0004 and CHAIR in Onco-Innovation from Faculty of Medicine, University of Porto (FMUP).